Thalassemias: Overview of Pathophysiology and Treatment

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

K. Fertrin

Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Taher

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

Mitapivat for Thalassemia: Results From the Ph3 ENERGIZE-T Study

Stefan Eber

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

Laboratory Evaluation and Diagnosis of Thalassemia

Norafiza Mohd Yasin

Beyond Transfusion: Current Treatment Options for Managing Thalassem…

Abdulrahman Nasiri

Optimal Life-Long Management and Curative Therapies for Transfusion-…

Robert Klaassen

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Peslak

Principles of Iron Management in Thalassemia

Nita Radhakrishnan

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red Cell …

Insights from 2023 ASH Annual Meeting

K. Kuo

Molecular Basis of Thalassemia

Norafiza Mohd Yasin

ASH 2023 Insights: "A Novel Beta Globin Frameshift Mutation Causing …

Insights from 2023 ASH Annual Meeting

L. Bilston

State-of-the-Art in Managing Thalassemias

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Cappellini

Principles of Transfusion Therapy for Thalassemia

Nita Radhakrishnan

Treatment of Thalassemia From Transplant to Novel Agents

Nita Radhakrishnan

Mitapivat in Adults With Alpha- or Beta-Non-Transfusion-Dependent Th…

Ali Taher

Importance of PK Activation in Thalassemias

Ilham Youssry